Cost-effectiveness analysis for triple markers serum screening for Down’s syndrome in Thai setting

Viroj Wiwanitkit¹,²,³

¹Hainan Medical University, China, ²Faculty of Medicine, University of Nis, Serbia, ³Joseph Ayobabalola University, Nigeria

BACKGROUND: Down’s syndrome is an important congenital chromosomal disorder that can be seen around the world. The antenatal screening for this disorder is an important processing in present obstetrics.

OBJECTIVE: Due to the concept of first do no harm, the use of noninvasive test is recommended. The triple marker screening test has been introduced for a few years and acceptable for its efficacy.

RESULT: However, an important concern is on its cost-effectiveness. Here, the author analyze and present the cost-effectiveness of the triple markers serum screening for Down’s syndrome in Thai setting.

CONCLUSION: According to this work, the cost per effectiveness of triple markers serum screening is slightly lower than standard amniocentesis test.

Key words: Down’s syndrome, screening, serum, triple markers

Introduction

Down’s syndrome is an important congenital chromosomal disorder that can be seen around the world.¹ This syndrome is the most common chromosomal disorder that the case can be alive for many years. However, the quality of life of the patient is usually poor due to the fact that all cases have mental retardation.² The patients become the big problem of their families and can be the social burden.

Materials and Methods

This work is a cost-effectiveness study. The standard medical economics analysis was performed. The protocol in this work is the same as previously published in international publications.³⁻⁸ The context is assigned as Thailand. Here, the cost is assigned as the price of laboratory test quoted at the referencing laboratory in Bangkok Thailand (Special Laboratory, Bangkok, Thailand). The effectiveness is assigned as reported effectiveness in screening or the diagnostic sensitivity, which is hereby referenced to the previously published paper from Thailand.⁹ The cost-effectiveness is hereby calculated by the formula “cost-effectiveness = cost/effectiveness” as used in the referencing papers.⁶⁻⁸ Furthermore, the
author uses the same cost-effectiveness analysis to assess the standard amniocentesis test as a standard comparison.

Results

According to this work, for the triple markers screening, the cost is equal to 100 US dollar and the effectiveness is equal to 85.7%. The derived is equal to 116.7 US dollar. For the standard amniocentesis, the cost is equal to 116.7 US dollar and the effectiveness is equal to 87.3%. The derived cost-effectiveness is equal to 133.7 US dollar. It seems that the cost per effectiveness of triple marker serum screening is lower than that of standard amniocentesis test.

Discussion

To perform an antenatal test is the present concept in preventive fetal medicine.[3] In case that the defected fetus is diagnosed, the consideration for therapeutic abortion might be considered. Due to the high prevalence of Down’s syndrome around the world, the attempt to perform an antenatal test is set around the world, including to Thailand.[10] There are several methods for screening Down’s syndrome in Thailand and the triple markers serum screening is also in use.

It is no doubt that the diagnostic property of the triple markers serum screening is acceptable. However, the issue to be discussed is on the cost-effectiveness. Some previous reports mentioned for the cost-effectiveness of using triple markers serum screening[11,12] while the others mentioned that the test was not cost-effective.[13] Hence, to make a decision to implement this test in any setting, the evaluation for cost-effectiveness is needed. According to this work, the cost per effectiveness of triple markers serum screening is slightly lower than standard amniocentesis test. However, this still means that the triple markers serum screening test is more effective. In addition, due to the less invasiveness comparing to standard amniocentesis test, it is recommended to use triple markers serum screening for antenatal screening for Down’s syndrome in Thailand.

Conclusion

In Thai context, the triple markers serum screening is more cost-effective than standard amniocentesis test in screening for Down’s syndrome.

References

1. Zellweger H. Mongolism – Down’s syndrome. Ergeb Inn Med Kinderheilkd 1965;22:268-363.
2. Goodman MJ, Brixner DI. New therapies for treating Down syndrome require quality of life measurement. Am J Med Genet A 2013;161A:639-41.
3. Chamberlain G. ABC of antenatal care. Detection and management of congenital abnormalities – I. BMJ 1991;302:949-50.
4. Mittal R, Varghese RM, Puliyl JM. Antenatal diagnosis of Down syndrome: How good is state of the art. J Indian Med Assoc 2009;107:36-38.
5. Aldred SK, Deeks JJ, Guo B, Neilson JP, Alfrevic Z. Second trimester serum tests for Down’s syndrome screening. Cochrane Database Syst Rev 2012;6:CD009925.
6. Wiwanitkit V. CA-125 and risk of malignancy index for screening for malignancy in fertile aged females with ovarian cyst, which is more cost effectiveness? Indian J Med Paediatr Oncol 2013;34:72-3.
7. Wiwanitkit V. Screening for syphilis in pregnancy: Which is the proper method? Arch Gynecol Obstet 2007;276:629-31.
8. Wiwanitkit V. A cost utility analysis of the right method for screening hemoglobin E among Thai pregnant women. Arch Gynecol Obstet 2006;274:88-90.
9. Lamlerkritikkul S, Chandeying V. Experience on triple markers serum screening for Down’s syndrome fetus in Hat Yai, Regional Hospital. J Med Assoc Thai 2007;90:1970-6.
10. Wasant P, Rajchagool C. Down syndrome parents’ support group in Thailand Siriraj Hospital, fifteen years experience: A review. J Med Assoc Thai 2009;92:1256-62.
11. Shackley P, McGuire A, Boyd PA, Dennis J, Fitchett M, Kay J, et al. An economic appraisal of alternative pre-natal screening programmes for Down’s syndrome. J Public Health Med 1993;15:175-84.
12. Cunningham GC, Tomkinson DG. Cost and effectiveness of the California triple marker prenatal screening program. Genet Med 1999;1:199-206.
13. Li DZ. Contingent triple-screening for Down syndrome in the second trimester is not a cost-effective pre-natal screening strategy in Mainland Chinese population. Prenat Diagn 2010;30:493.